SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 36.31 |
Enterprise Value ($M) | 71.43 |
Book Value ($M) | -4.08 |
Book Value / Share | -0.12 |
Price / Book | -8.90 |
NCAV ($M) | -23.89 |
NCAV / Share | -0.69 |
Price / NCAV | -1.52 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.45 |
Return on Assets (ROA) | -1.26 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.41 |
Current Ratio | 1.41 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 24.79 |
Assets | 44.59 |
Liabilities | 48.68 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -18.70 |
Net Income | -24.77 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -26.77 |
Cash from Investing | 18.21 |
Cash from Financing | 26.69 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Armistice Capital, Llc | 4.99 | 7.85 | |
13G/A | Point72 Asset Management, L.P. | 0.00 | -100.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
30,771 | 191,112 | 16.10 | |
85,423 | 323,262 | 26.43 | |
84,452 | 276,174 | 30.58 | |
72,810 | 235,461 | 30.92 | |
(click for more detail) |
Similar Companies | |
---|---|
INTS – Intensity Therapeutics, Inc. | IPA – ImmunoPrecise Antibodies Ltd. |
IRD – Opus Genetics, Inc. | JAGX – Jaguar Health, Inc. |
JSPR – Jasper Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io